Streptococcus pneumoniae infection medical therapy: Difference between revisions

Jump to navigation Jump to search
m (Changes made per Mahshid's request)
 
(6 intermediate revisions by 4 users not shown)
Line 1: Line 1:
{{Streptococcus pneumoniae}}
__NOTOC__
{{Streptococcus pneumoniae infection}}
{{CMG}}
{{CMG}}


==Overview==
==Overview==
Antimicrobial therapy is the mainstay of therapy for infections caused by ''Streptococcus pneumoniae''.


==Medical therapy==
==Medical therapy==
Historically, treatment relied primarily on β-lactam antibioticsIn the [[1960s]], nearly all strains of ''S. pneumoniae'' were susceptible to [[penicillin]], but since that time, there has been an increasing prevalence of penicillin [[antibiotic resistance|resistance]], especially in areas of high [[antibiotic]] use. A varying proportion of strains may also be resistant to [[cephalosporin]]s, [[macrolide]]s (such as erythromycin), [[tetracycline]], [[clindamycin]] and the [[quinolone]]s.  Penicillin-resistant strains are more likely to be resistant to other antibiotics. Most isolates remain susceptible to [[vancomycin]], though its use in a β-lactam-susceptible isolate is less desirable because of tissue distribution of the drug and concerns of development of vancomycin resistance. More advanced beta-lactam antibiotics ([[cephalosporins]]) are commonly used in combination with other drugs to treat meningitis and community-acquired pneumonia. In adults, recently developed fluoroquinolones such as [[levofloxacin]] and [[moxifloxacin]] are often used to provide empiric coverage for patients with pneumonia. [[Susceptibility testing]] should be routine, with empiric antibiotic treatment guided by resistance patterns in the community in which the organism was acquired, pending the results. There is currently debate as to how relevant the results of susceptibility testing are to clinical outcome.<ref name="ClinInfectDis2006-Peterson">{{cite journal | author=Peterson LR | title=Penicillins for treatment of pneumococcal pneumonia: does in vitro resistance really matter? | journal=Clin Infect Dis | year=2006 | pages=224-33 | volume=42 | issue=2 | id={{PMID|16355333}} }}</ref><ref name="ClinInfectDis2006-Tleyjeh">{{cite journal | author=Tleyjeh IM, Tlaygeh HM, Hejal R, Montori VM, Baddour LM | title=The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis | journal=Clin Infect Dis | year=2006 | pages=788-97 | volume=42 | issue=6 | id={{PMID|16477555}} }}</ref>  There is slight clinical evidence that penicillins may act synergistically with macrolides to improve outcomes.<ref>{{cite journal | title=Addition of a Macrolide to a β-Lactam based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia | author=Martínez JA, Horcajada JP, Almela M, ''et al.'' | journal=Clin Infect Dis | volume=36 | year=2003 | pages=389–395 | DOI=10.1086/367541 | id=PMID 12567294 }}</ref>
:* Streptococcus pneumonia treatment
::* 1. '''Lung (Community-acquired pneumonia)'''<ref name="pmid17278083">{{cite journal| author=Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC et al.| title=Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. | journal=Clin Infect Dis | year= 2007 | volume= 44 Suppl 2 | issue=  | pages= S27-72 | pmid=17278083 | doi=10.1086/511159 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17278083 }} </ref>
:::* 1.1 '''Penicillin sensitive (minimum inhibitory concentration < 2 mcg/ml)'''
::::* Preferred regimen: [[Penicillin G]] 5 to 24 MU IV in equally divided doses q4-6h, [[Amoxicillin]] 1 g PO tid (+/- macrolide)
::::* Alternative regimen:  Macrolides ([[Azithromycin]] (IV) 500 mg IV qd for at least 2 days followed by 500 mg PO qd 7 to 10 days or [[Clarithromycin]] extended-release tablets 1000 mg PO qd for 7 days) and Oral Cephalosporins-[[Cefpodoxime]] 200 mg PO bd, ([[Cefprozil]] 500 mg PO bd, [[Cefditoren]] 400 mg PO bd, [[Cefdinir]] 300 mg PO bd), {{or}} parenteral Cephalosporins-[[Ceftriaxone]] 2 g IV q24h (or [[Cefotaxime]] 1-2 g IV q6-8h), [[Clindamycin]] 600 to 1200 mg IV or IM q6-12h, do not give single IM doses >600 mg; IV infusion rates should not exceed 30 mg/min , [[Doxycycline]] 100 mg PO bd, respiratory flouroquniolones.
:::* 1.2 '''[[Penicillin]]-resistant ([[Penicillin]] minimum inhibitory concentration ≥2)'''
::::* Preferred regimen: [[Ceftriaxone]] 2 g IV q24h (or [[Cefotaxime]] 1-2 g IV q6-8h), respiratory [[Flouroquniolones]] [[Levofloxacin]] (Levaquin) 500 mg IV/PO q24h for 7 to 14 days or 750 mg IV/PO q24h for 5 days  (or [[Moxifloxacin]] (Avelox) 400 mg PO/IV over 60 minutes q24h for 7 to 14 days)
::::* Alternative regimen: [[Vancomycin]] 2 g/day IV q6-12h over at least 60 minutes, [[Linezolid]] 600 mg IV/PO q12h for 7 to 21 days , high-dose [[Amoxicillin]] (3 g qd with [[Penicillin]] minimum concentration of inhibitory <4 mcg/mL).
::* 2.'''Endocarditis'''<ref name="pmid15956145">{{cite journal| author=Baddour LM, Wilson WR, Bayer AS, Fowler VG, Bolger AF, Levison ME et al.| title=Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. | journal=Circulation | year= 2005 | volume= 111 | issue= 23 | pages= e394-434 | pmid=15956145 | doi=10.1161/CIRCULATIONAHA.105.165564 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15956145 }}</ref>
:::* Preferred regimen (1):  Aqueous crystalline [[Penicillin-G]]  6 MU q4-6h IV  for 4 weeks
:::* Preferred regimen (2) (who are unable to tolerate beta lactams therapy): [[Vancomycin]] 15 mg/kg IV every 12 hours (target trough concentration, 10 to 15 mcg/mL) [9]; for troughs of 15 to 20 mcg/mL (MIC, 1 mcg/mL or less), dose 15 to 20 mg/kg (actual body weight) IV every 8 to 12 hours for most patients with normal renal function
:::* Preferred regimen (3) (If the isolate is resistant (MIC 2 g/mL) to cefotaxime): [[Cefotaxime]] 1-2 g q8-12h IV or IM (max dose: 12 g/24 hr) {{and}} [[Vancomycin]] 15 mg/kg/day IV q12h {{and}} [[Rifampin]] 300 mg IV/PO q8h for 6 weeks, in combination with appropriate antimicrobial therapy
:::* Alternative regimen (1): [[Cefazolin]]  0.5-2 g q8h IV or IM (max dose: 12 g/24 hr)
:::* Alternative regimen (2): [[Ceftriaxone]] 2 g IV q12h
::::* Note : Streptococcus pneumoniae with intermediate doses minimum inhibitory concentration (MIC) 0.12 g/mL–0.5 g/mL [[Penicillin]] resistance (MIC 0.1 to 1.0 g/mL) or high [[Penicillin]] resistance (MIC 2.0 g/mL) is being recovered from patients with bacteremia.
::* 3. '''Sinuses (sinusitis)'''<ref name="pmid22438350">{{cite journal| author=Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ, Hicks LA et al.| title=IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. | journal=Clin Infect Dis | year= 2012 | volume= 54 | issue= 8 | pages= e72-e112 | pmid=22438350 | doi=10.1093/cid/cir1043 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22438350  }} </ref>
:::* Empiric therapy
::::* 3.1 '''For initial empiric treatment of acute bacterial rhinosinusitis in adults'''
:::::* Preferred regimen: [[Amoxicillin]] 500 mg/[[Clavulanate]] 125 mg PO tid or [[Amoxicillin]] 875 mg/[[Clavulanate]] 125 mg PO bid for 5 to 7 days recommended by the Infectious Disease Society of America (IDSA)
:::::* Alternative regimen (1): [[Doxycycline]] 100 mg PO q12h
::::::* Note: [[Doxycycline]] can be used in patients with [[Penicillin]] allergy.
:::::* Alternative regimen (2): A respiratory [[Fluoroquinolone]] ([[Levofloxacin]] or [[Moxifloxacin]]) is another recommended drug for [[Penicillin]]-allergic patients.
::::* 3.2 '''For second-line high-dose therapy for acute bacterial rhinosinusitis in adults'''
:::::* Preferred regimen: [[Amoxicillin]] 2 g/[[Clavulanate]] 125 mg PO bid recommended by the Infectious Disease Society of America (IDSA).
:::::* Note: The second line high dose therapy is recommended in adults who have failed initial therapy, in regions of high endemic rates (10% or greater) of invasive [[Penicillin]]-nonsusceptible Streptococcus pneumoniae, severe infection.
::* 4. '''Bronchi (acute exacerbation of chronic bronchitis)'''<ref>{{cite book | last = Bartlett | first = John | title = Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases | publisher = Jones and Bartlett Learning | location = Burlington, MA | year = 2012 | isbn = 978-1449625580 }}</ref>
:::* Preferred regimen (1): [[Amoxicillin]] 875 mg PO q12h or 500 mg PO q8h
:::* Preferred regimen (2): [[Doxycycline]] 100 mg PO q12h
::* 5. '''CNS (meningitis)'''<ref name="pmid15494903">{{cite journal| author=Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM et al.| title=Practice guidelines for the management of bacterial meningitis. | journal=Clin Infect Dis | year= 2004 | volume= 39 | issue= 9 | pages= 1267-84 | pmid=15494903 | doi=10.1086/425368 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15494903  }} </ref>
:::* Empiric therapy
::::* Preferred regimen: [[Vancomycin]] 15 mg/kg/day IV q12h {{and}} a third-generation cephalosporin ([[Ceftriaxone]] 2 g IV q12h {{or}} [[Cefotaxime]] 2 g IV q4h or 3 g q6h) {{and}} [[Rifampin]] 600 mg IV qd in combination with [[Vancomycin]]
::::* Alternative regimen: [[Meropenem]], fluoroquinolones 
::::: Note: Middle ear infections (otitis media), peritoneum infections (spontaneous bacterial peritonitis), pericardium infections (purulent pericarditis), skin infections (cellulitis) and eye infections (conjunctivitis) caused by Streptococcus pneumonia.
::* '''Prevention'''
:::* 1. Pneumovax (23-valent) prevents bacteremia; impact on rates of CAP are modest or nil.
:::* 2. Prevnar vaccine for children <2 yrs age  prevents invasive pneumococcal infection in adults by herd effect. Impact is impressive with rates of invasive pneumococcal infection down 80% in peds and 20-40% in adults.
:::* 3. Risk for bacteremia in splenectomy, HIV, smokers, black race, multiple myeloma, asthma.


==References==
==References==
Line 11: Line 49:


[[Category:Disease]]
[[Category:Disease]]
[[Category:Infectious disease]]
 
[[Category:Pulmonology]]
[[Category:Pulmonology]]



Latest revision as of 18:52, 18 September 2017

Streptococcus pneumoniae infection Microchapters

Home

Patient Information

Overview

Classification

Community Acquired Pneumonia
Endocarditis
Sinusitis
Bronchitis
Meningitis

Cause

Laboratory Findings

Medical Therapy

Primary Prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Antimicrobial therapy is the mainstay of therapy for infections caused by Streptococcus pneumoniae.

Medical therapy

  • Streptococcus pneumonia treatment
  • 1. Lung (Community-acquired pneumonia)[1]
  • 1.1 Penicillin sensitive (minimum inhibitory concentration < 2 mcg/ml)
  • Preferred regimen: Penicillin G 5 to 24 MU IV in equally divided doses q4-6h, Amoxicillin 1 g PO tid (+/- macrolide)
  • Alternative regimen: Macrolides (Azithromycin (IV) 500 mg IV qd for at least 2 days followed by 500 mg PO qd 7 to 10 days or Clarithromycin extended-release tablets 1000 mg PO qd for 7 days) and Oral Cephalosporins-Cefpodoxime 200 mg PO bd, (Cefprozil 500 mg PO bd, Cefditoren 400 mg PO bd, Cefdinir 300 mg PO bd), OR parenteral Cephalosporins-Ceftriaxone 2 g IV q24h (or Cefotaxime 1-2 g IV q6-8h), Clindamycin 600 to 1200 mg IV or IM q6-12h, do not give single IM doses >600 mg; IV infusion rates should not exceed 30 mg/min , Doxycycline 100 mg PO bd, respiratory flouroquniolones.
  • 2.Endocarditis[2]
  • Preferred regimen (1): Aqueous crystalline Penicillin-G 6 MU q4-6h IV for 4 weeks
  • Preferred regimen (2) (who are unable to tolerate beta lactams therapy): Vancomycin 15 mg/kg IV every 12 hours (target trough concentration, 10 to 15 mcg/mL) [9]; for troughs of 15 to 20 mcg/mL (MIC, 1 mcg/mL or less), dose 15 to 20 mg/kg (actual body weight) IV every 8 to 12 hours for most patients with normal renal function
  • Preferred regimen (3) (If the isolate is resistant (MIC 2 g/mL) to cefotaxime): Cefotaxime 1-2 g q8-12h IV or IM (max dose: 12 g/24 hr) AND Vancomycin 15 mg/kg/day IV q12h AND Rifampin 300 mg IV/PO q8h for 6 weeks, in combination with appropriate antimicrobial therapy
  • Alternative regimen (1): Cefazolin 0.5-2 g q8h IV or IM (max dose: 12 g/24 hr)
  • Alternative regimen (2): Ceftriaxone 2 g IV q12h
  • Note : Streptococcus pneumoniae with intermediate doses minimum inhibitory concentration (MIC) 0.12 g/mL–0.5 g/mL Penicillin resistance (MIC 0.1 to 1.0 g/mL) or high Penicillin resistance (MIC 2.0 g/mL) is being recovered from patients with bacteremia.
  • 3. Sinuses (sinusitis)[3]
  • Empiric therapy
  • 3.1 For initial empiric treatment of acute bacterial rhinosinusitis in adults
  • 3.2 For second-line high-dose therapy for acute bacterial rhinosinusitis in adults
  • Preferred regimen: Amoxicillin 2 g/Clavulanate 125 mg PO bid recommended by the Infectious Disease Society of America (IDSA).
  • Note: The second line high dose therapy is recommended in adults who have failed initial therapy, in regions of high endemic rates (10% or greater) of invasive Penicillin-nonsusceptible Streptococcus pneumoniae, severe infection.
  • 4. Bronchi (acute exacerbation of chronic bronchitis)[4]
  • Preferred regimen (1): Amoxicillin 875 mg PO q12h or 500 mg PO q8h
  • Preferred regimen (2): Doxycycline 100 mg PO q12h
  • 5. CNS (meningitis)[5]
  • Empiric therapy
Note: Middle ear infections (otitis media), peritoneum infections (spontaneous bacterial peritonitis), pericardium infections (purulent pericarditis), skin infections (cellulitis) and eye infections (conjunctivitis) caused by Streptococcus pneumonia.
  • Prevention
  • 1. Pneumovax (23-valent) prevents bacteremia; impact on rates of CAP are modest or nil.
  • 2. Prevnar vaccine for children <2 yrs age prevents invasive pneumococcal infection in adults by herd effect. Impact is impressive with rates of invasive pneumococcal infection down 80% in peds and 20-40% in adults.
  • 3. Risk for bacteremia in splenectomy, HIV, smokers, black race, multiple myeloma, asthma.

References

  1. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC; et al. (2007). "Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults". Clin Infect Dis. 44 Suppl 2: S27–72. doi:10.1086/511159. PMID 17278083.
  2. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Bolger AF, Levison ME; et al. (2005). "Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America". Circulation. 111 (23): e394–434. doi:10.1161/CIRCULATIONAHA.105.165564. PMID 15956145.
  3. Chow AW, Benninger MS, Brook I, Brozek JL, Goldstein EJ, Hicks LA; et al. (2012). "IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults". Clin Infect Dis. 54 (8): e72–e112. doi:10.1093/cid/cir1043. PMID 22438350.
  4. Bartlett, John (2012). Johns Hopkins ABX guide : diagnosis and treatment of infectious diseases. Burlington, MA: Jones and Bartlett Learning. ISBN 978-1449625580.
  5. Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM; et al. (2004). "Practice guidelines for the management of bacterial meningitis". Clin Infect Dis. 39 (9): 1267–84. doi:10.1086/425368. PMID 15494903.


Template:WH Template:WS